BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza vaccine ...

Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create new ...

Thailand Pharmaceutical Industry, according to Fitch Solutions, the pharmaceutical market in Southeast Asia has a market size ...

Overall, the attraction of Pfizer as an investment is its level of diversification with several different growing drug ...